KYinno focuses on providing end-to-end oncology drug discovery services and customized product development. Its core platform offers cell-based assay validation, high-throughput compound screening, antibody discovery, and phage-display technologies that help biopharma partners accelerate immuno-oncology and next-generation kinase inhibitor programs. The company positions itself as both a service provider and a co-developer, aiming to build proprietary pipelines alongside client projects. Proceeds from its latest financing will be directed toward expanding laboratory infrastructure, upgrading technological capabilities, and advancing internal project pipelines. Although detailed operating metrics such as revenue or user counts were not disclosed, the capital raise underscores investor confidence in KYinno’s business model and growth trajectory. The presence of returning shareholder Yuanhui Chuanyi suggests continued internal support and validation.

Total raised

$51M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2025